{"id":2405,"date":"2015-08-25T18:59:45","date_gmt":"2015-08-25T18:59:45","guid":{"rendered":"https:\/\/www.lymphoma.ca\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/"},"modified":"2015-08-25T18:59:45","modified_gmt":"2015-08-25T18:59:45","slug":"publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/","title":{"rendered":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab"},"content":{"rendered":"<p>Selon les r\u00e9sultats d\u00e9finitifs de l\u2019\u00e9tude GAUSS, publi\u00e9s dans le Journal of Clinical Oncology, l\u2019usage de l\u2019obinutuzumab (Gazyva)<br \/>\n<!--more--><\/p>\n<h2>Le Journal of Clinical Oncology publie les donn\u00e9es de l\u2019\u00e9tude GAUSS<\/h2>\n<p><span style=\"line-height: 24px;\">Selon les r\u00e9sultats d\u00e9finitifs de l\u2019\u00e9tude GAUSS, publi\u00e9s dans le <\/span><em style=\"line-height: 24px;\">Journal of Clinical Oncology<\/em><span style=\"line-height: 24px;\">, l\u2019usage de l\u2019obinutuzumab (Gazyva) a permis d\u2019am\u00e9liorer le taux de r\u00e9ponse globale au traitement des patients atteints d\u2019un lymphome non hodgkinien indolent (LNHi) en rechute. En outre, le m\u00e9dicament a r\u00e9v\u00e9l\u00e9 un niveau de toxicit\u00e9 acceptable compar\u00e9 \u00e0 celui du rituximab (Rituxan). Toutefois, le meilleur taux de r\u00e9ponse n\u2019a pas entra\u00een\u00e9 d\u2019am\u00e9lioration de la survie sans progression, laissant ainsi un doute sur le r\u00f4le de l\u2019obinutuzumab \u00e0 cet \u00e9gard.<\/span><\/p>\n<p><a href=\"http:\/\/www.onclive.com\/web-exclusives\/obinutuzumabs-benefit-in-inhl-unclear-after-gauss-results-published#sthash.Xhbxaajr.dpuf\">http:\/\/www.onclive.com\/web-exclusives\/obinutuzumabs-benefit-in-inhl-unclear-after-gauss-results-published#sthash.Xhbxaajr.dpuf<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selon les r\u00e9sultats d\u00e9finitifs de l\u2019\u00e9tude GAUSS, publi\u00e9s dans le Journal of Clinical Oncology, l\u2019usage de l\u2019obinutuzumab (Gazyva)<\/p>\n","protected":false},"author":1,"featured_media":1771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10,17],"tags":[],"class_list":{"0":"post-2405","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nouvelles","8":"category-recherche"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"Selon les r\u00e9sultats d\u00e9finitifs de l\u2019\u00e9tude GAUSS, publi\u00e9s dans le Journal of Clinical Oncology, l\u2019usage de l\u2019obinutuzumab (Gazyva)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2015-08-25T18:59:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab\",\"datePublished\":\"2015-08-25T18:59:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"articleSection\":[\"Nouvelles\",\"Recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\",\"name\":\"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"datePublished\":\"2015-08-25T18:59:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"width\":700,\"height\":300,\"caption\":\"masthead_ph_shadows\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/","og_locale":"fr_FR","og_type":"article","og_title":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada","og_description":"Selon les r\u00e9sultats d\u00e9finitifs de l\u2019\u00e9tude GAUSS, publi\u00e9s dans le Journal of Clinical Oncology, l\u2019usage de l\u2019obinutuzumab (Gazyva)","og_url":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2015-08-25T18:59:45+00:00","og_image":[{"width":700,"height":300,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab","datePublished":"2015-08-25T18:59:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","articleSection":["Nouvelles","Recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/","url":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/","name":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","datePublished":"2015-08-25T18:59:45+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","width":700,"height":300,"caption":"masthead_ph_shadows"},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/publication-dune-nouvelle-etude-concernant-lusage-de-lobinutuzumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Publication d\u2019une nouvelle \u00e9tude concernant l\u2019usage de l\u2019obinutuzumab"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=2405"}],"version-history":[{"count":0,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2405\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/1771"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=2405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=2405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=2405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}